Francisco M. Marty

19.5k total citations · 2 hit papers
204 papers, 8.2k citations indexed

About

Francisco M. Marty is a scholar working on Epidemiology, Infectious Diseases and Oncology. According to data from OpenAlex, Francisco M. Marty has authored 204 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Epidemiology, 98 papers in Infectious Diseases and 42 papers in Oncology. Recurrent topics in Francisco M. Marty's work include Antifungal resistance and susceptibility (62 papers), Fungal Infections and Studies (48 papers) and Cytomegalovirus and herpesvirus research (40 papers). Francisco M. Marty is often cited by papers focused on Antifungal resistance and susceptibility (62 papers), Fungal Infections and Studies (48 papers) and Cytomegalovirus and herpesvirus research (40 papers). Francisco M. Marty collaborates with scholars based in United States, Germany and Belgium. Francisco M. Marty's co-authors include Lindsey R. Baden, Sophia Koo, Sarah P. Hammond, Michael Boeckh, Robert J. Soiffer, Genovefa A. Papanicolaou, Julie M. Bryar, Joseph H. Antin, Kaiwen Chen and Roy F. Chemaly and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Francisco M. Marty

190 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation

2014 286 citations Timothy J. Henrich, Emily Hanhauser et al. profile →
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

2021 167 citations Catherine Cordonnier, Johan Maertens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francisco M. Marty United States	52	4.8k	3.5k	1.5k	784	758	204	8.2k
Raymund R. Razonable United States	58	8.1k 1.7×	3.8k 1.1×	2.3k 1.5×	1.5k 2.0×	980 1.3×	290	11.1k
Ajit P. Limaye United States	55	5.5k 1.1×	3.1k 0.9×	2.7k 1.8×	793 1.0×	846 1.1×	182	9.3k
Robin K. Avery United States	53	6.0k 1.2×	4.7k 1.4×	1.8k 1.2×	1.8k 2.3×	1.2k 1.6×	226	10.6k
Fausto Baldanti Italy	55	7.1k 1.5×	5.8k 1.6×	2.0k 1.3×	736 0.9×	216 0.3×	434	12.3k
Thomas F. Smith United States	57	6.6k 1.4×	2.6k 0.7×	1.5k 1.0×	751 1.0×	314 0.4×	232	10.2k
M. Ho Hong Kong	44	2.7k 0.6×	1.5k 0.4×	2.4k 1.6×	1.0k 1.3×	330 0.4×	171	7.3k
Juan Berenguer Spain	58	7.0k 1.4×	3.4k 1.0×	1.2k 0.8×	2.5k 3.2×	521 0.7×	467	13.7k
Nicolas J. Mueller Switzerland	41	2.1k 0.4×	1.4k 0.4×	1.3k 0.9×	1.4k 1.7×	528 0.7×	177	5.2k
Robert H. Rubin United States	48	5.5k 1.1×	1.7k 0.5×	1.4k 1.0×	1.8k 2.3×	1.4k 1.8×	136	9.4k
Atul Humar Canada	67	10.6k 2.2×	4.1k 1.2×	2.9k 2.0×	2.2k 2.8×	1.6k 2.1×	275	14.4k

Countries citing papers authored by Francisco M. Marty

Since Specialization

Citations

This map shows the geographic impact of Francisco M. Marty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco M. Marty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco M. Marty more than expected).

Fields of papers citing papers by Francisco M. Marty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco M. Marty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco M. Marty. The network helps show where Francisco M. Marty may publish in the future.

Co-authorship network of co-authors of Francisco M. Marty

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco M. Marty. A scholar is included among the top collaborators of Francisco M. Marty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco M. Marty. Francisco M. Marty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Somersan-Karakaya, Selin, Eleftherios Mylonakis, Ernesto Oviedo‐Orta, et al.. (2023). Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial. Open Forum Infectious Diseases. 10(5). ofad211–ofad211. 1 indexed citations

Ison, Michael G., et al.. (2022). Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States. Transplant Infectious Disease. 24(4). e13866–e13866. 3 indexed citations

Cheng, Alexandre Pellan, Matthew P. Cheng, Joan Sesing Lenz, et al.. (2022). Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proceedings of the National Academy of Sciences. 119(4). 29 indexed citations

Chen, Evan C., Yiwen Liu, Eric S. Winer, et al.. (2022). Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia & lymphoma. 63(8). 1934–1941. 21 indexed citations

Kauke‐Navarro, Martin, Adriana C. Panayi, Ali‐Farid Safi, et al.. (2021). Full facial retransplantation in a female patient—Technical, immunologic, and clinical considerations. American Journal of Transplantation. 21(10). 3472–3480. 37 indexed citations

Wongboonsin, Janewit, et al.. (2021). Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir. Kidney International Reports. 6(7). 1987–1991. 4 indexed citations

Slavin, Monica A., Yee‐Chun Chen, Catherine Cordonnier, et al.. (2021). When to change treatment of acute invasive aspergillosis: an expert viewpoint. Journal of Antimicrobial Chemotherapy. 77(1). 16–23. 20 indexed citations

Zhou, Eric S., et al.. (2021). Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications. Open Forum Infectious Diseases. 9(1). ofab582–ofab582.

Chen, Kaiwen, Matthew P. Cheng, Anne McDonnell, et al.. (2021). Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis. Transplant Infectious Disease. 23(4). e13619–e13619. 9 indexed citations

10.

Ricciuti, Biagio, Sarah P. Hammond, Francisco M. Marty, et al.. (2020). Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 145. 181–185. 31 indexed citations

11.

Vedula, Rahul S., Matthew P. Cheng, Dimitrios Farmakiotis, et al.. (2020). Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease. Blood Advances. 5(1). 54–60. 10 indexed citations

12.

Hogan, Louise E., Emily Hanhauser, Kristen S. Hobbs, et al.. (2018). Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. PLoS ONE. 13(5). e0197298–e0197298. 6 indexed citations

13.

Kaneko, Tsuyoshi, et al.. (2014). Triple opportunistic pulmonary cavitary disease after cord blood transplantation. Transplant Infectious Disease. 16(5). 818–821. 2 indexed citations

14.

Chandraker, Anil, Ramon Arscott, George J. Murphy, et al.. (2014). The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant. American Journal of Transplantation. 14(6). 1446–1452. 93 indexed citations

15.

Marty, Francisco M., Drew J. Winston, Scott D. Rowley, et al.. (2013). CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 369(13). 1227–1236. 267 indexed citations

16.

Hammond, Sarah P., et al.. (2011). Molecular Methods To Improve Diagnosis and Identification of Mucormycosis. Journal of Clinical Microbiology. 49(6). 2151–2153. 150 indexed citations

17.

Koo, Sophia, Julie M. Bryar, Lindsey R. Baden, & Francisco M. Marty. (2010). Prognostic Features of Galactomannan Antigenemia in Galactomannan-Positive Invasive Aspergillosis. Journal of Clinical Microbiology. 48(4). 1255–1260. 71 indexed citations

18.

Henrich, Timothy J., Francisco M. Marty, Danny A. Milner, & Aaron R. Thorner. (2009). Disseminated Geotrichum candidum infection in a patient with relapsed acute myelogenous leukemia following allogeneic stem cell transplantation and review of the literature. Transplant Infectious Disease. 11(5). 458–462. 31 indexed citations

19.

Marty, Francisco M., et al.. (2007). Der Impfschutz gegen die Zeckenenzephalitis hält viel länger als bisher angenommen. Schweizerische Ärztezeitung. 88(45). 1903–1906. 1 indexed citations

20.

Marty, Francisco M., et al.. (2006). Reactivity of (1→3)-β- d -Glucan Assay with Commonly Used Intravenous Antimicrobials. Antimicrobial Agents and Chemotherapy. 50(10). 3450–3453. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact